

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Anti-AR (ARv7 Splice Variant) rabbit monoclonal antibody [RM7]

RRID:AB_2716436

Type: Antibody

Proper Citation

RevMAb Biosciences Cat# 31-1109-00, RRID:AB_2716436

Antibody Information

URL: http://antibodyregistry.org/AB_2716436

Proper Citation: RevMAb Biosciences Cat# 31-1109-00, RRID:AB_2716436

Target Antigen: AR (ARv7 Splice Variant)

Host Organism: rabbit

Clonality: unknown

Comments: Originating manufacturer of this product. Applications: WB, ICC, IHC. This antibody reacts to androgen receptor splice variant 7 (AR-V7). No cross reactivity with wild type androgen receptor.

Antibody Name: Anti-AR (ARv7 Splice Variant) rabbit monoclonal antibody [RM7]

Description: This unknown targets AR (ARv7 Splice Variant)

Target Organism: human

Clone ID: RM7

Antibody ID: AB_2716436

Vendor: RevMAb Biosciences

Catalog Number: 31-1109-00

Record Creation Time: 20231110T033805+0000

Record Last Update: 20260829T135038+0000

Ratings and Alerts

No rating or validation information has been found for Anti-AR (ARv7 Splice Variant) rabbit monoclonal antibody [RM7].

No alerts have been found for Anti-AR (ARv7 Splice Variant) rabbit monoclonal antibody [RM7].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Brim BC, et al. (2025) Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models. Cancer research communications, 5(8), 1396.

Andolfi C, et al. (2024) MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer. Endocrinology, 165(10).

Anselmino N, et al. (2024) Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(10), 2272.

Poluben L, et al. (2024) Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer. Cell reports, 44(1), 115089.

Dhital B, et al. (2023) Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. Cell reports. Medicine, 4(2), 100937.

Hung CL, et al. (2023) Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer. EBioMedicine, 90, 104500.

Sowalsky AG, et al. (2022) Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(16), 3509.

Tang S, et al. (2022) A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell reports, 38(8), 110417.

Dufour CR, et al. (2022) The mTOR chromatin-bound interactome in prostate cancer. Cell reports, 38(12), 110534.

Kim S, et al. (2022) AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. *eLife*, 11.

Richters A, et al. (2021) Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. *Cell chemical biology*, 28(2), 134.

Cato L, et al. (2019) ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. *Cancer cell*, 35(3), 401.